Stem cell trial for knee osteoarthritis underway

Regeneus (ASX:RGS) shares jumped over 20% today as the regenerative medicine company announced the first patient to be treated by Progenza, its mesenchymal stem cell (MSC) therapy treatment for knee osteoarthritis. The patient was the first of 20 …

[Read the full article here]

Comments are closed.